Go Pro
→ Trump and Bernie agree on this (From Porter & Company) (Ad)tc pixel Free PRPH Stock Alerts

ProPhase Labs (PRPH) Competitors

ProPhase Labs logo
$0.01 0.00 (-16.89%)
As of 09/18/2026 03:51 PM Eastern
Compare

PRPH vs. NMTR, EVFM, CMND, HEPA, and CERO

Should you buy ProPhase Labs stock or one of its competitors? ProPhase Labs's main competitors and comparable companies include 9 Meters Biopharma (NMTR), Evofem Biosciences (EVFM), Clearmind Medicine (CMND), Hepion Pharmaceuticals (HEPA), and CERo Therapeutics (CERO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ProPhase Labs compare to 9 Meters Biopharma?

ProPhase Labs (NASDAQ:PRPH) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Given 9 Meters Biopharma's higher probable upside, analysts plainly believe 9 Meters Biopharma is more favorable than ProPhase Labs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProPhase Labs
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

ProPhase Labs has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

In the previous week, ProPhase Labs' average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score.

Company Overall Sentiment
ProPhase Labs Neutral
9 Meters Biopharma Neutral

9 Meters Biopharma has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. ProPhase Labs' return on equity of -482.05% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ProPhase Labs-825.01% -482.05% -88.90%
9 Meters Biopharma N/A -584.97%-159.45%

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

9 Meters Biopharma has lower revenue, but higher earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProPhase Labs$5.06M0.04-$53.36M-$2.25N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

Summary

ProPhase Labs and 9 Meters Biopharma tied by winning 6 of the 12 factors compared between the two stocks.

How does ProPhase Labs compare to Evofem Biosciences?

ProPhase Labs (NASDAQ:PRPH) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

ProPhase Labs has a beta of 0.06, indicating that its share price is 94% less volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.3, indicating that its share price is 230% less volatile than the broader market.

Evofem Biosciences has a net margin of -46.42% compared to ProPhase Labs' net margin of -825.01%. Evofem Biosciences' return on equity of -91.97% beat ProPhase Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
ProPhase Labs-825.01% -482.05% -88.90%
Evofem Biosciences -46.42%-91.97%-61.93%

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Evofem Biosciences has higher revenue and earnings than ProPhase Labs. Evofem Biosciences is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProPhase Labs$5.06M0.04-$53.36M-$2.25N/A
Evofem Biosciences$11.39M0.09$52.98M-$0.13N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProPhase Labs
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, ProPhase Labs' average media sentiment score of 0.00 equaled Evofem Biosciences'average media sentiment score.

Company Overall Sentiment
ProPhase Labs Neutral
Evofem Biosciences Neutral

Summary

Evofem Biosciences beats ProPhase Labs on 7 of the 12 factors compared between the two stocks.

How does ProPhase Labs compare to Clearmind Medicine?

Clearmind Medicine (NASDAQ:CMND) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Clearmind Medicine has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Clearmind Medicine's return on equity of -88.53% beat ProPhase Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -88.53% -61.62%
ProPhase Labs -825.01%-482.05%-88.90%

96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Clearmind Medicine has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.06, suggesting that its share price is 94% less volatile than the broader market.

Clearmind Medicine has higher earnings, but lower revenue than ProPhase Labs. Clearmind Medicine is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$40.55N/A
ProPhase Labs$5.06M0.04-$53.36M-$2.25N/A

In the previous week, Clearmind Medicine had 2 more articles in the media than ProPhase Labs. MarketBeat recorded 2 mentions for Clearmind Medicine and 0 mentions for ProPhase Labs. Clearmind Medicine's average media sentiment score of 0.67 beat ProPhase Labs' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the media.

Company Overall Sentiment
Clearmind Medicine Positive
ProPhase Labs Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
ProPhase Labs
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Clearmind Medicine beats ProPhase Labs on 8 of the 13 factors compared between the two stocks.

How does ProPhase Labs compare to Hepion Pharmaceuticals?

Hepion Pharmaceuticals (NASDAQ:HEPA) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Hepion Pharmaceuticals has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. ProPhase Labs' return on equity of -482.05% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hepion PharmaceuticalsN/A -812.56% -207.31%
ProPhase Labs -825.01%-482.05%-88.90%

Hepion Pharmaceuticals has higher earnings, but lower revenue than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A
ProPhase Labs$5.06M0.04-$53.36M-$2.25N/A

Hepion Pharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.06, indicating that its share price is 94% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hepion Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
ProPhase Labs
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

17.2% of Hepion Pharmaceuticals shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 0.1% of Hepion Pharmaceuticals shares are held by insiders. Comparatively, 9.6% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Hepion Pharmaceuticals' average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company Overall Sentiment
Hepion Pharmaceuticals Neutral
ProPhase Labs Neutral

Summary

ProPhase Labs beats Hepion Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does ProPhase Labs compare to CERo Therapeutics?

ProPhase Labs (NASDAQ:PRPH) and CERo Therapeutics (NASDAQ:CERO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CERo Therapeutics has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. CERo Therapeutics' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
ProPhase Labs-825.01% -482.05% -88.90%
CERo Therapeutics N/A N/A -209.40%

CERo Therapeutics has lower revenue, but higher earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProPhase Labs$5.06M0.04-$53.36M-$2.25N/A
CERo TherapeuticsN/AN/A-$8.30M-$9.84N/A

In the previous week, ProPhase Labs' average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company Overall Sentiment
ProPhase Labs Neutral
CERo Therapeutics Neutral

CERo Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 294,017.65%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CERo Therapeutics is more favorable than ProPhase Labs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProPhase Labs
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

ProPhase Labs has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Summary

CERo Therapeutics beats ProPhase Labs on 8 of the 12 factors compared between the two stocks.

Get ProPhase Labs News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRPH vs. The Competition

Export
MetricProPhase LabsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$223K$12.49B$7.25B$12.95B
Dividend YieldN/A2.64%2.57%12.80%
P/E Ratio-0.01644.99210.2920.60
Price / Sales0.04753.54656.3793.45
Price / CashN/A15.0828.1334.74
Price / Book0.0110.5110.506.32
Net Income-$53.36M$2.82B$3.49B$358.20M
7 Day PerformanceN/A1.69%0.59%1.12%
1 Month PerformanceN/A0.24%-1.74%-2.39%
1 Year PerformanceN/A3.95%18.13%5.35%

ProPhase Labs Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRPH
ProPhase Labs
N/A$0.01
-16.9%		N/A-99.7%$223K$5.06MN/A130
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/AN/A20
EVFM
Evofem Biosciences
N/A$0.01
flat		N/A-47.9%$1.02M$11.39MN/A120
CMND
Clearmind Medicine
1.5461 of 5 stars		$0.86
-8.4%		N/A-99.8%$960KN/AN/AN/A
HEPA
Hepion Pharmaceuticals
N/A$0.08
flat		N/A+38.6%$903KN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PRPH) was last updated on 9/20/2026 by MarketBeat.com Staff.
From Our Partners
$40,000,000,000,000
The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...
American Alternative | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Elon Musk to Trigger Next AI Wave on November 11th?
Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...
Brownstone Research | Sponsoredtc pixel
No Wallstreet. No Advisor. No Problem.
Savings accounts pay just 0.58 percent interest. Andy Howard, co-founder of Meridian Capital, says liquidity p...
Awesomely | Sponsoredtc pixel
The end of AI data centers coming?
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel
Gold majors have a big problem
Newmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...
Golden Portfolio | Sponsoredtc pixel
The hidden costs of a hands-off retirement account
Contributing to your 401(k) consistently is good financial behavior - but contributing and optimizing are two ...
SmartAsset | Sponsoredtc pixel